- Genentech, a unit of Roche Holdings AG (OTC:RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC).
- The trial evaluated tiragolumab plus Tecentriq (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment in 534 NSCLC patients.
- The study did not meet its co-primary endpoint of progression-free survival.
- At this first analysis, the other co-primary endpoint of overall survival was immature, and the study will continue until the next planned analysis.
- Also See: Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial.
- A numerical improvement was observed in both co-primary endpoints.
- Data suggest that tiragolumab plus Tecentriq was well-tolerated, and no new safety signals were identified when adding tiragolumab.
- Tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region. It selectively binds to TIGIT, a novel inhibitory immune checkpoint, which suppresses the immune response to cancer.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks